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Abstract: The APCDD1 (adenomatosis polyposis coli down-regulated 1) gene is an inhibitor of the Wnt signaling pathway, and a 
rare mutation of this gene has been associated with hereditary hypotrichosis simplex. In this study, the authors aimed to investigate 
whether common APCDD1 gene polymorphisms contribute to the development of androgenic alopecia. Patients (n = 210) with 
androgenic alopecia and 98 controls were investigated. SNPs (Single nucleotide polymorphisms) in the coding region of the gene 
were sequenced. A significant difference in genotype distribution was found for the c.1781C/T, p.L476L SNP (rs3185480) of the 
APCDD1 gene. This SNP is located in exon 5 and is associated with a 3.5- and a 2.8-fold increase in risk for the development of 
androgenic alopecia for homozygote (CI 0.933-13.125; nominal regression P = 0.063) and heterozygote (CI 1.086-7.217; nominal 
regression P = 0.033) carriers, respectively. These data suggest that the rs3185480 polymorphism contributes to the development of 
androgenic alopecia. Protein expression experiments revealed that the polymorphism is associated with reduced APCDD1 protein 
abundance. This reduction is likely due to altered codon usage for leucine from a preferred codon (CTC) to a rare codon (CTT), 
which might influence translation efficiency and, thus, APCDD1 protein level.  
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1. Introduction 
Adenomatosis polyposis coli down-regulated 1 
(APCDD1) was initially isolated in a search for genes 
that were down-regulated after introduction of an 
adenovirus construct expressing the wild type APC 
gene into SW480 colon cancer cells [1]. APCDD1 is a 
membrane-bound glycoprotein, conserved throughout 
vertebrate evolution [1]. The APCDD1 gene is 
abundantly expressed in follicular dermal papilla cells, 
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hair matrix and hair shafts and is an inhibitor of the 
Wnt signaling pathway [2-4]. In addition to those 
associated with hair, APCDD1 is expressed widely in 
various cell types and, therefore, may regulate several 
biological processes controlled by Wnt signaling [2, 5].  
A recurrent missense mutation (p.Leu9Arg) of this 
gene has been shown to be associated with the rare 
hair condition hereditary hypotrichosis simplex 
(OMIM 605389), which is an autosomal dominant 
form of nonsyndromic alopecia [3, 4]. The p.Leu9Arg 
mutation is located in the signal sequence of the 
APCDD1 protein and impairs its transport to the 
plasma membrane [3]. The hereditary hypotrichosis 
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simplex associated with p.Leu9Arg-APCDD1 is 
characterized by normal hair at birth and a progressive 
hair loss starting in early childhood. Hair loss affects 
the scalp only or the scalp and axillary and pubic hair, 
but not beard hair [3, 4]. The p.Leu9Arg-APCDD1 
associated hypotrichosis also involves follicle 
miniaturization, resulting in the development of thin 
and short hair, which is also a typical feature of 
androgenetic alopecia (AGA, OMIM 109200) [3, 4, 6].  
AGA, the most common hair-loss disorder, is a 
multifactorial and polygenic disorder with several 
well-known acquired and inherited factors in its 
etiology. The disease occurs in both men and women 
and is characterized by hair loss following defined 
patterns [7, 8]. The patterns of hair loss for men are 
described by the Hamilton-Norwood scale and for 
women by the Ludwig scale [7]. Initial signs of AGA 
usually develop during teenage years and lead to 
progressive hair loss. Its frequency increases with age 
and affects up to 80% Caucasian men and 42% 
Caucasian women [9, 10]. AGA is characterized by 
the transformation from terminal to vellus hairs, 
shortening of the anagen phase, miniaturization of the 
hair follicles (and, thus, progressive thinning of the 
hair shafts) and progressive hair loss [10].  
A recurrent missense mutation of the APCDD1 
gene results in the development of a rare hair disorder, 
hereditary hypotrichosis simplex. This observation led 
us to ask whether common SNPs of this gene 
contribute to the pathogenesis of AGA.  
2. Patients and Methods 
2.1 Patients 
Three hundred and eight Hungarian individuals 
were enrolled into the study. Two hundred and ten of 
the enrolled individuals were AGA patients and 98 
were healthy individuals. The severity of AGA was 
classified according to the Hamilton-Norwood scale 
for men and the Ludwig scale for women. The female 
to male ratio was 2:1 in both AGA and control groups. 
The average age was 45 ± 27 years for AGA patients 
and 43 ± 25 for controls. The average body weight 
was 75 ± 13 kg for AGA patients and 68 ± 11 kg for 
controls. The range of heights for all enrolled 
individuals was between 160 cm and 170 cm in both 
groups. Patients with polycystic ovary syndrome, 
hormonal replacement therapy, vitiligo, thyroid 
disease and autoimmune disease were excluded from 
the study. Demographical and clinical data of the 
enrolled individuals are summarized in Table 1. 
Informed consent approved by the internal review 
board were obtained from all enrolled individuals, and 
the study was conducted according to the Declaration 
of Helsinki Principles.  
2.2 Genotyping APCDD1 Gene Polymorphisms 
After the informed consent was obtained, peripheral 
blood samples were taken from the enrolled 
individuals, and genomic DNA was isolated by a 
BioRobot EZ1 DSP Workstation (QIAGEN; Godollo, 
Hungary). Coding regions and the flanking introns of 
the APCDD1 gene were amplified with the PCR 
(polymerase chain reaction). Sequences used for 
primers were obtained from the UCSC Genome 
Browser (www.genome.ucsc.edu). Direct sequencing 
of the amplified PCR products was performed using 
an ABI Prism 7000 Sequencer (Life Technologies; 
Budapest, Hungary). The genotypes of the 
polymorphisms of the APCDD1 gene were 
determined.  
 
Table 1  Clinical data of enrolled individuals. 
Clinical characteristics of enrolled individuals (n = 308) Patients with AGA (n = 210) Controls (n = 98) 
Female to male ratio 1.7:1 2.1:1 
Age (years) 45 ± 27 43 ± 25 
Height (cm) 167 ± 9 163 ± 7 
Weight (kg) 75 ± 13 68 ± 11 
Body mass index (kg/m2) 26 ± 4 25 ± 5 




2.3 Genomic DNA, Total RNA and Protein 
Preparation from Tonsil Samples  
As the APCDD1 protein is expressed at high levels 
in human tonsils and tonsils can be easily processed 
for protein studies, functional studies were carried out 
on tonsil samples. Informed consent was obtained 
from elective tonsillectomy patients affected by 
chronic tonsillitis, and tonsil samples (n = 20; 10 
males and 10 females). Genomic DNA was isolated 
from the tonsil samples using the DNeasy Blood & 
Tissue Kit (QIAGEN). The fifth exon of the APCDD1 
gene was PCR amplified and sequenced. Genotype of 
the rs3185480 polymorphism of the APCDD1 gene 
was determined for all tonsil samples. After 
identifying three tonsil samples from each genotype 
(homozygous common allele, heterozygous, 
homozygous rare allele, nine samples total), selected 
samples were processed for total RNA and protein 
extraction. 
Total RNA from the nine selected tonsil samples 
was extracted using the RNeasy Fibrous Tissue Mini 
Kit (QIAGEN). Fragments overlapping exons 4 and 5 
and exon 5 and the 3′ untranslated region were 
amplified by PCR and real-time quantitative RT-PCR. 
Primer and probe sequences were obtained from the 
Universal Probe Library Set 
(www.roche-applied-science.com). PCR product size 
was determined by gel electrophoresis.  
Total protein extracts were prepared from the   
nine tonsil samples using the following protein   
lysis buffer: 1.5% sodium dodecyl sulphate     
(SDS), 62.5 mM Tris-HCl (pH 6.8), 5 mM 
ethylenediaminetetraacetic acid, 5% 
2-mercapto-ethanol, 1 µg/mL antipain, 1 µg/mL 
chymostatin and 1 µg/mL leupeptin (all chemicals 
were obtained from Sigma-Aldrich, St Louis, MO, 
USA). Lysates were precleared by centrifugation and 
supernatants were stored at –20 °C. Concentration of 
the protein samples was determined using the BCA 
Protein Assay Kit (Santa Cruz Biotechnology; 
Budapest, Hungary). Protein quantities in sample 
volumes used for western blot were checked by 10% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and Coomassie brilliant blue (Sigma-Aldrich) 
staining.  
2.4 Western Blot Analysis  
Equal amounts of protein extracts of the tonsil 
samples (n = 9) were run on SDS-PAGE and 
transferred to nitrocellulose membrane (BioRad 
Laboratories, Hercules, CA, USA). Membranes were 
blocked by incubation in Tris-buffered saline (150 
mM NaCl and 25 mM Tris, pH 7.4) containing 0.05% 
Tween 20 (Sigma-Aldrich) and 3% non-fat dry milk 
(Fluka Chemie AG, Neu-Buchs, Switzerland) for 2 h 
at room temperature and subsequently incubated 
overnight at 4 °C with anti-APCDD1 antibody 
produced in mouse (SAB1408369, Sigma-Aldrich) at 
a 1:100 dilution. In addition, a mouse monoclonal 
antibody (A5441, Sigma-Aldrich) at a 1:500 dilution 
was used to detect β-actin. Alkaline 
phosphatase-conjugated goat anti-mouse IgG 
(Sigma-Aldrich) was used as secondary antibody at a 
1:4000 dilution in the blocking buffer for 2 h at room 
temperature. The blots were developed with 
5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium (Sigma-Aldrich) as a substrate. The 
expression profile of the protein samples was 
determined by semi-quantitative analysis using 
densitometry analysis of the intensity of bands on the 
western blots. 
2.5 Statistical Analysis 
The statistical significance of differences in the 
distribution of the APCDD1 gene polymorphism 
genotypes was assessed by Chi2-probe. Risk 
assessment for the development of AGA for carriers 
the rs3185480 polymorphism in heterozygous or in 
homozygous form was performed by nominal 
regression analysis. All statistical analyses were 
performed using SPSS software (IBM; Budapest, 
Hungary). 
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3. Results and Discussion 
3.1 The Frequency of the Rare Allele of the rs3185480 
Polymorphism Significantly Higher in AGA Patients 
Genotypes of polymorphisms located in the coding 
regions of the APCDD1 gene were determined for all 
enrolled individuals (n = 308). Of the investigated 
polymorphisms, only five, rs3748413, rs3748414, 
rs3748415, rs3185480 and rs60421798, had a rare 
allele frequency greater than 0.1 (Fig. 1). Since we 
were unable to perform statistical analysis for 
polymorphisms with a rare allele frequency less than 
0.1, they were excluded from further analysis.  
Three polymorphisms (rs3748413, rs3748414, 
rs3748415) are located in exon 3 of the APCDD1 gene. 
These polymorphisms showed no difference in the 
distribution of the allele frequencies or the genotypes 
between AGA patients (n = 210) and controls (n = 98). 
As these polymorphisms had highly similar allele 
frequencies, linkage disequilibrium analysis was 
performed and confirmed that these polymorphisms 
belong to the same haplotype (r2 = 1; Fig. 2.). 
Two polymorphisms (rs3185480, rs60421798) are 
located in exon 5 of the APCDD1 gene. Comparing 
the allele frequencies for AGA patients and controls, 
we found a significant difference (Chi2-probe P = 
0.0109) in the rare allele frequency of the rs3185480 
polymorphism (Fig. 1.). We also compared the 
distribution of genotypes for the rs3185480 
polymorphism between AGA patients and controls 
and found a significant difference (Chi2-probe P < 
0.001; Table 2). 
Nominal regression analysis demonstrated a 3.5- 
and a 2.8-fold increased risk for the development of 
AGA for homozygote (confidence interval, CI, 0.933 
– 13.125, P = 0.063) and heterozygote (CI 1.086 – 
7.217, P = 0.033) carriers of the rare allele. The 
rs3185480 polymorphism results in a synonymous 
codon change: both alleles encode leucine and, thus, 
do not result in a change in the amino acid sequence 
of the APCDD1 protein (Fig. 3).  
We did not detect an association with AGA of the 
rs60421798 polymorphism, also occurring in exon 5, 
based on allele frequency and genotype distribution. 
 
 
Fig. 1  Allele frequencies of polymorphisms located in the coding region of the APCDD1 gene. 
Five polymorphisms in APCDD1 coding regions with rare allele frequencies greater than 0.1 were identified. Comparing the allele 
frequency for AGA patients with healthy controls, we found significant difference in the distribution of the rare allele of the 
rs3185480 polymorphism. The other investigated polymorphisms showed no association with AGA. 




Fig. 2  Linkage disequilibrium analysis.  
Three polymorphisms of exon 3 (rs3748413, rs3748414 and rs3748415) are inherited together. The two SNPs of exon 5 (rs3185480, 
rs60421798) are not involved in this haplotype. 
 
Table 2  Distribution of rs3185480 genotypes. 
Alleles at the rs3185480 polymorphism 
of the APCDD1 gene 




Homozygous rare (TT) 
n (%) 
Patients with AGA (n = 210) 37 (18) 100 (48) 73 (35) 
Controls (n = 98) 28 (29) 60 (61) 10 (10) 
 
The two polymorphisms occurring in exon 5 did not 
exhibit linkage with each other or with the 
polymorphisms located in exon 3. 
3.2 In Silico Analysis and the Assessment of 
Alternative Splice Variants  
The rs3185480 polymorphism is a synonymous 
variant (c.1781C/T, p.Leu476Leu), and we desired to 
determine whether the sequence change has a 
functional consequence or whether it is simply a 
marker for AGA. Some synonymous changes have 
been reported to have a pathogenic role. In Netherton 
syndrome, for example, a synonymous mutation 
(c.891C/T, p.Cys297Cys) in the exon 11 of the 
SPINK5 gene, which alters an exonic splicing 
regulatory element, is causative for the disease [11]. 
Inspired by these data, in silico and in vitro mRNA 
analyses were carried out.  
We performed an in silico prediction of exonic 
splicing regulatory elements for the region 
surrounding the rs3185480 polymorphism for both 
alleles using the ESEfinder 3.0 software 
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home) and found that the rs3185480 
polymorphism is located within a exonic splicing 
regulatory element: GCAGAGGACCTCGCAGAA (the 
position of the rs3185480 polymorphism is underlined). 
This result suggests that the rs3185480 polymorphism 
may alter the splicing of the APCDD1 mRNA.  
To confirm the in silico result, in vitro mRNA 
analysis was performed with tonsil samples that had 
been genotyped for the rs3185480 polymorphism. For 
 





Fig. 3  The rs3185480 polymorphism of the APCDD1 gene causes a synonymous codon change.  
DNA sequencing results for the (a) homozygous common, (b) heterozygous and (c) homozygous rare alleles of the rs3185480 
polymorphism.  
 
each of the three genotypes of the rs3185480 
polymorphism (homozygous common, heterozygous 
and homozygous rare), three independent samples 
were chosen (nine samples total). Fragment size was 
examined by RT-PCR and real-time quantitative 
RT-PCR for fragments amplified from a region that 
includes the splice junction between exons 4 and 5 
and a region that includes part of exon 5 and the 3′ 
untranslated region of the APCDD1 mRNA. No size 
difference was observed for the fragments amplified 
from tissues of all three genotypes (data not shown).  
Although an in silico analysis of the APCDD1 gene 
sequence suggested that the rs3185480 polymorphism 
might alter splicing, no difference in mRNA length 
was observed for rs3185480 genotypes. We conclude 
that it is unlikely that the rs3185480 polymorphism 
results in splicing variants. 
3.3 Affects on Translational Efficiency by the 
Synonymous Codon Change for the rs3185480 
Polymorphism 
Since our mRNA studies could not answer the 
question how the rs3185480 polymorphism of the 
APCDD1 gene contributes to AGA, further functional 
studies were performed. Most of the amino acids are 
coded by multiple codons: some of these codons occur 
with higher frequency in the human genome, while 
others with lower ones 
(http://www.genscript.com/cgi-bin/tools/codon_freq_t
able). For a given amino acid, for example for leucine 
CTC and CTG are the most common codons, 
encoding 60% of the total leucine in the human 
genome, while CTT, CTA, TTA and TTG altogether 
encodes only 40% of the total leucine. Codon-usage 
bias has been observed in almost all genomes and is 
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thought to result from selection for efficient and 
accurate translation of highly expressed genes [12, 13]. 
Codon usage is also implicated in the control of 
transcription, splicing and RNA structure [13]. 
Altered codon usage in the Neurospora FREQUENCY 
(FRQ) protein, for example, affects circadian clock 
function by influencing expression level, 
conformation, phosphorylation profile and stability of 
the FRQ protein [13].  
Therefore, we investigated whether the altered 
codon usage of leucine due to the presence of the 
common or the rare allele of the rs3185480 
polymorphism influences the translation efficacy and 
thus the level of the APCDD1 protein. To investigate 
this hypothesis, tonsil samples expressing the 
APCDD1 protein at high levels were used for Western 
blot analysis. The samples used in our protein studies 
were genotyped for the rs3185480 polymorphism and 
nine samples were chosen to represent each of the 
three genotypes with three independent samples.  
APCDD1 protein levels were detected by western 
blot analysis for the genotyped tonsil samples and 
normalized  to β-actin  levels  (Figs.  4a  and  4b). 
Different  levels  of  APCDD1  expression  were 
observed for  the three genotypes (Fig. 4c). Although 
the differences were not statistically significant, the 
tendency is  clear and suggests the presence of the 
rs3185480 polymorphism is associated with decreased 
APCDD1 expression in a dose-dependent manner. 
Further immune-histochemical investigations of hair 
 
 
Fig. 4  Western blot analysis.  
Expression profiles of (a) the APCDD1 and (b) the β-actin proteins in tonsil samples genotyped for the rs3185480 polymorphism. (c) 
Semi-quantitative analysis of western blots demonstrated decreased protein expression in tonsil samples for heterozygous and 
homozygous rare genotypes compared to samples with homozygous common genotype of the rs3185480 polymorphism.  




follicles from individuals of all three rs3185480 
genotypes are necessary to determine whether this 
polymorphism has the same effect on protein 
translation observed for tonsils. Results from such 
experiments could likely correlate rs3185480 
genotype and AGA phenotype. 
4. Conclusions 
Here we report on the association of the rs3185480 
polymorphism of the APCDD1 gene and AGA. Since 
the rs3185480 polymorphism is a synonymous one 
and does not cause amino acid change on the sequence 
of the APCDD1 protein, we investigated whether this 
polymorphism can influence APCDD1 expression or 
it is a marker of AGA. Our in silico analysis suggested 
that the rs3185480 polymorphism might influence 
mRNA splicing since it is located in an exonic 
splicing regulatory element, however we could not 
prove this finding by in vitro mRNA studies. To 
further investigate the possible effect of the rs3185480 
polymorphism on the expression level of the 
APCDD1 protein, we have performed Western blot 
analysis on tonsils samples previously genotyped for 
the investigated polymorphism and detected altered 
APCDD1 expression levels in samples carrying the 
rare alleles of the rs3185480 polymorphism. 
Functional data suggested that the rs3185480 
polymorphism might alter translation efficacy and 
thus the level of the APCDD1 protein through altering 
codon usage of leucine from the preferred to a rare 
one. Further immune-histochemical investigations on 
the hair follicles of individuals with homozygous wild 
type, heterozygous or homozygous rare genotype of 
the rs3185480 polymorphism may answer whether 
this polymorphism has the same effect on protein 
translation we saw in the tonsils. This set of 
experiments would provide a direct link between the 
genotype of the rs3185480 polymorphism and the 
phenotype of AGA.  
In summary, our results demonstrated that the 
synonymous rs3185480 polymorphism of the 
APCDD1 gene is associated with the development of 
the most common hair disorder, AGA. Our functional 
analysis suggests that this polymorphism may 
influence the level of the APCDD1 protein through 
codon-usage bias. 
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